BTIG analyst Julian Harrison downgraded VYNE Therapeutics (NASDAQ: VYNE) from Buy to Neutral.The analyst comments: "Repibresib did not meet the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE